Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (11-20 of 182) with videos related to

Pageof 19
Sort By:
Current Hematologic Malignancy Reports|April 29, 2010
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspectiveMartha Wadleigh, D Gary Gilliland
Cancer Cell|July 18, 2006
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesisJennifer L Rocnik, D Gary Gilliland
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2002
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantationD Gary Gilliland, John G Gribben
Cell Cycle (Georgetown, Tex.)|March 17, 2004
Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemiaIris T Chan, D Gary Gilliland
Current Opinion in Hematology|November 30, 2006
JAK-2 mutations and their relevance to myeloproliferative diseaseRoss L Levine, D Gary Gilliland
Current Opinion in Genetics & Development|January 9, 2007
Jak2: normal function and role in hematopoietic disordersJames N Ihle, D Gary Gilliland
Blood|September 10, 2008
Myeloproliferative disordersRoss L Levine, D Gary Gilliland
Annual Review of Medicine|October 9, 2007
A role for JAK2 mutations in myeloproliferative diseasesKelly J Morgan, D Gary Gilliland
Blood|August 15, 2002
The roles of FLT3 in hematopoiesis and leukemiaD Gary Gilliland, James D Griffin
Best Practice & Research. Clinical Haematology|March 18, 2008
Can FLT3 inhibitors overcome resistance in AML?Winnie F Tam, D Gary Gilliland
Pageof 19

Showing results (11-20 of 182) with videos related to

Sort By:
Pageof 19
Current Hematologic Malignancy Reports|April 29, 2010
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspectiveMartha Wadleigh, D Gary Gilliland
Cancer Cell|July 18, 2006
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesisJennifer L Rocnik, D Gary Gilliland
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2002
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantationD Gary Gilliland, John G Gribben
Cell Cycle (Georgetown, Tex.)|March 17, 2004
Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemiaIris T Chan, D Gary Gilliland
Current Opinion in Hematology|November 30, 2006
JAK-2 mutations and their relevance to myeloproliferative diseaseRoss L Levine, D Gary Gilliland
Current Opinion in Genetics & Development|January 9, 2007
Jak2: normal function and role in hematopoietic disordersJames N Ihle, D Gary Gilliland
Blood|September 10, 2008
Myeloproliferative disordersRoss L Levine, D Gary Gilliland
Annual Review of Medicine|October 9, 2007
A role for JAK2 mutations in myeloproliferative diseasesKelly J Morgan, D Gary Gilliland
Blood|August 15, 2002
The roles of FLT3 in hematopoiesis and leukemiaD Gary Gilliland, James D Griffin
Best Practice & Research. Clinical Haematology|March 18, 2008
Can FLT3 inhibitors overcome resistance in AML?Winnie F Tam, D Gary Gilliland
Pageof 19